Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Trial register facet

Trial records in obesity and overweight in adults — page 7

208 records bearing on obesity and overweight in adults.

Showing 0 records on this page

Records

208 documents · page 7 of 9

Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.

RecordCompoundPhaseStatusDesignRandomisedYearCertainty
SCALE-SLEEP-APNOEA-DDIprogramme recordLiraglutidePhase 1ReportedRandomised crossover2016Very low
SCALE-SLEEP-APNOEA-HEPATIC-IMPprogramme recordLiraglutidePhase 1ReportedPhase 1 ascending dose2016Very low
SCALE-SLEEP-APNOEA-REGIONAL-JPprogramme recordLiraglutidePhase 3ReportedRandomised, double-blind, placebo-controlled2016Very low
SCALE-OBESITYLiraglutidePhase 3ReportedRandomised, double-blind, placebo-controlled3,7312015High
SCALE-OBESITY-REGIONAL-CNprogramme recordLiraglutidePhase 3ReportedRandomised, double-blind, placebo-controlled2015Very low
SCALE-OBESITY-QOLprogramme recordLiraglutidePhase 3ReportedRandomised, double-blind, placebo-controlled2015Very low
SCALE-OBESITY-BODY-COMPprogramme recordLiraglutidePhase 3ReportedRandomised, double-blind, placebo-controlled2015Very low
SCALE-OBESITY-REGIONAL-JPprogramme recordLiraglutidePhase 3ReportedRandomised, double-blind, placebo-controlled2015Very low
SCALE-OBESITY-ELDERLYprogramme recordLiraglutidePhase 3ReportedRandomised, double-blind, placebo-controlled2015Very low
AOD-PH2B-OBESITYAOD-9604Phase 2bProgramme discontinuedRandomised, double-blind, placebo-controlled5362007Not rated
PRAM-OBESITY-PH2PramlintidePhase 2ReportedRandomised, double-blind, placebo-controlled4112007Low
AOD-PH2B-OBESITY-QOLprogramme recordAOD-9604Phase 2bReportedRandomised, double-blind, placebo-controlled2007Very low
PRAM-OBESITY-PH2-OLEprogramme recordPramlintidePhase 2ReportedSingle-arm open-label2007Very low
AOD-PH2B-OBESITY-REGIONAL-CNprogramme recordAOD-9604Phase 3ReportedRandomised, double-blind, placebo-controlled2007Very low
PRAM-OBESITY-PH2-ELDERLYprogramme recordPramlintidePhase 2ReportedRandomised, double-blind, placebo-controlled2007Very low
AOD-PH2B-OBESITY-REGIONAL-JPprogramme recordAOD-9604Phase 3ReportedRandomised, double-blind, placebo-controlled2007Very low
PRAM-OBESITY-PH2-BIOMARKERprogramme recordPramlintidePhase 2ReportedRandomised, double-blind, placebo-controlled2007Very low
AOD-PH2B-OBESITY-BODY-COMPprogramme recordAOD-9604Phase 2bReportedRandomised, double-blind, placebo-controlled2007Very low
PRAM-OBESITY-PH2-ADHERENCEprogramme recordPramlintidePhase 2ReportedObservational2007Very low
AOD-PH2B-OBESITY-DDIprogramme recordAOD-9604Phase 1ReportedRandomised crossover2007Very low
TRIUMPH-1RetatrutidePhase 3OngoingRandomised, double-blind, placebo-controlledNot rated
TRIUMPH-2RetatrutidePhase 3OngoingRandomised, double-blind, placebo-controlledNot rated
TRIUMPH-3RetatrutidePhase 3OngoingRandomised, double-blind, placebo-controlledNot rated
TRIUMPH-4RetatrutidePhase 3OngoingRandomised, double-blind, placebo-controlledNot rated

page 7 of 9

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.